Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccines
AssigneeMassachusetts Institute of Technology
InventorsRahul Raman, Xiaoying Koh, Karthik Viswanathan, Ram Sasisekharan, Aarthi Chandrasekaran
Life of this patent
Estimating the term…
Abstract
The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.
Claims46
An engineered influenza hemagglutinin (HA) polypeptide that possesses at least 90% overall sequence identity with a reference HA polypeptide of SEQ ID NO:
- 1, which engineered HA polypeptide characterized in that its amino acid sequence includes:
- an amino acid residue (“Residue 137”) at a position corresponding to position 137 of SEQ ID NO:1 that is selected from the group consisting of arginine, lysine, glutamine, methionine and histidine;
- and
- an amino acid residue (“Residue 193”) at a position corresponding to position 193 of SEQ ID NO:1 that is selected from the group consisting of alanine, aspartic acid, glutamic acid, leucine, isoleucine, methionine, serine, threonine, cysteine, and valine;
- and
- an amino acid residue (“Residue 226”) at a position corresponding to position 226 of SEQ ID NO:1 that is selected from the group consisting of alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan and valine;
- and
- an amino acid residue (“Residue 228”) at a position corresponding to position 228 of SEQ ID NO:1 that is selected from the group consisting of arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, glycine, threonine, and tyrosine.
An engineered HA polypeptide characterized in that its amino acid sequence includes the Residue 137 is arginine;
- Residue 193 is threonine;
- Residue 226 is leucine;
- and Residue 228 is serine.
An engineered HA polypeptide wherein the improvement comprises the presence of
- an amino acid residue (“Residue 137”) at a position corresponding to position 137 of SEQ ID NO:1 that is selected from the group consisting of arginine, lysine, glutamine, methionine and histidine;
- and
- an amino acid residue (“Residue 193”) at a position corresponding to position 193 of SEQ ID NO:1 that is selected from the group consisting of alanine, aspartic acid, glutamic acid, leucine, isoleucine, methionine, serine, threonine, cysteine, and valine;
- and
- an amino acid residue (“Residue 226”) at a position corresponding to position 226 of SEQ ID NO:1 that is selected from the group consisting of alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan and valine;
- and
- an amino acid residue (“Residue 228”) at a position corresponding to position 228 of SEQ ID NO:1 that is selected from the group consisting of arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, glycine, threonine, and tyrosine.
An engineered HA polypeptide wherein the improvement comprises the presence of an arginine at Residue 137, a threonine at Residue 193, a leucine at Residue 226 and a serine at Residue 228.
Dependencies are inferred from the claim text.